Creating Value Through Breakthrough Science
We invest in early & late stage companies taking novel scientific approaches to address significant unmet needs in the life sciences and information technology sectors
More InfoOur Approach
New Science Ventures, LLC (NSV) is a Connecticut and London-based venture capital firm which invests in companies using novel scientific approaches in the Life Sciences and Information Technology sectors
Learn MoreNews
Paragraf, the first company in the world to mass produce graphene-based electronic devices using standard semiconductors processes, was named Business of the Year in the 33rd annual Business Weekly Awards on 14 September 2023. Co-founders Simon Thomas – the CEO – and CSO Professor Sir Colin Humphreys received the coveted
Read MoreVUV Analytics, Inc. is proud to announce the publication of ASTM D8519-23, a groundbreaking new method for the Determination of Hydrocarbon Types in Waste Plastic Process Oil using Gas Chromatography with Vacuum Ultraviolet Absorption Spectroscopy (GC-VUV). This method is the first of its kind, designed to accurately characterize WPPO produced
Read MoreVentyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that the first subject has been dosed in a Phase 1 trial of VTX3232, a novel central nervous system
Read MoreVentyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that the Company has completed patient enrollment in the Phase 2 trial of VTX002 in ulcerative colitis and the
Read MoreNovadip Biosciences SA (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has announced that the first patient has been implanted with its investigational tissue regeneration product, NVD-003, in its
Read MoreTrellis Bioscience Inc, a clinical stage privately held biotechnology company focused on the discovery and development of native human monoclonal antibodies, has announced a clinical proof-of-concept milestone from a planned interim analysis of the company's Phase 1 trial of its lead antibody, TRL1068 (calpurbatug), in patients with prosthetic joint infections
Read MoreParagraf, the only company in the world to mass produce graphene electronics using transfer-free graphene and standard semiconductor processes, has acquired Cardea Bio, the world’s leading producer of graphene-based biocompatible chips. Cardea Bio is to be renamed Paragraf USA and the San Diego facility, team and operations have already become
Read MoreVUV Analytics, Inc. has announced that it has raised $20 million in equity financing—led by existing investors S3 Ventures and New Science Ventures—bringing its total funding to over $36 million. The announcement follows the recent launch of the company’s LUMA product and a record year for revenue with its unit
Read MoreProterixBio, Inc. has announced the offering of the Presage® ST2 Assay as a testing service through ProterixBio’s high-complexity CLIA laboratory. This Assay has been FDA cleared for use in conjunction with clinical evaluation as an aid in assessing the prognosis of patients diagnosed with chronic heart failure. Heart failure is
Read MorePicocom, the 5G Open RAN baseband semiconductor and software specialist, has announced Antevia Networks has selected Picocom’s award-winning silicon technology to empower its new innovative 5G in-building solutions. The partnership combines Antevia Networks’ technology with Picocom’s latest generation 5G system-on-chip silicon to drive innovations to address the many challenges of
Read MoreIsorg, a pioneer in Organic PhotoDetectors (OPDs) and large area image sensors, announces further details on the company’s collaboration with Precise Biometrics, a leader in fingerprint verification software, on a new Fingerprint on Display (FoD) solution for the mobile industry. While increasing resolution unquestionably remains a major trend within the
Read MoreIsorg, a pioneer in Organic PhotoDetectors (OPDs) and large area image sensors, has announced the FBI certification of Bio1Print30, a large-area optical fingerprint sensor for applications where enhanced mobile security and nomad ID authentication are key. The Bio1Print30, a FAP30 (Fingerprint Acquisition Profile) device, whose core technology is compatible with
Read MoreNorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, has provided an update on its clinical pipeline of structurally engineered fatty acids (‘SEFAs’), a new class of fatty acids drugs, for the treatment
Read MoreNovadip Biosciences SA (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has announced positive data from its Phase 1/2 clinical trial evaluating the safety and clinical activity of its
Read MoreVentyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, has announced that the first patient has been dosed in a Phase 2 trial of its selective, allosteric TYK2 inhibitor VTX958 for
Read MoreResolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, has announced that its Phase II clinical trial of RSLV-132 in patients with long covid has been fully enrolled (NCT04944121). The randomized, double-blind, placebo- controlled study in patients with long covid who are suffering from debilitating fatigue has enrolled
Read MoreNovadip Biosciences (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has announced that it has raised an additional EUR 40 million in a Series B equity round and non-dilutive
Read MoreLeveraging its new Block 2 architecture, Phase Four announces Max-V, a revolutionary plasma propulsion system available in 2023. Phase Four, the creator of the radio-frequency thruster for satellite propulsion, has announced that it will expand its Maxwell turn-key plasma propulsion line and offer satellite manufacturers an industry-first high performance engine
Read MoreVentyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, has announced positive data from the company’s Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of VTX958, a
Read MoreWeaving together digital engineering and technology, Parker Aerospace today announced collaboration with Lockheed Martin and DUST Identity. The alliance implements DUST technology to connect Parker Aerospace products with Lockheed Martin aircraft to track parts from build to delivery and maintenance. The collaboration optimizes Parker Aerospace product traceability and supply chain
Read More

Our Companies
We focus on sectors that have strong decades-long tailwinds, where we have direct experience and where we can leverage our strong external networks to create value
Learn MoreOur Team
The team brings a wealth of investment experience and board expertise in the life sciences and information technology sectors across US and Europe
Learn MoreContact Us
Greenwich
500 West Putnam Avenue, Suite 400, Greenwich CT 06830
T: 212 688 5100 F: 646 844 9845
London
16 Old Queen Street, London SW1H 9HP
T: 020 3981 9092 F: 020 3981 9100